ATG14 Antibody

What is ATG14 and what is its functional significance in autophagy?

ATG14 (also known as BARKOR, KIAA0831, and Beclin 1-associated autophagy-related key regulator) is a 492 amino acid protein with a molecular mass of approximately 55.3 kDa that plays an essential role in both basal and inducible autophagy . ATG14 functions as a core component of the class III phosphatidylinositol 3-kinase (PI3KC3) complex by directing its localization to the pre-autophagosomal structure, which is critical for autophagosome formation . The protein has a distinctive subcellular distribution pattern across the membrane, cytoplasmic vesicles, endoplasmic reticulum, and cytoplasm, reflecting its multifunctional nature in the autophagy pathway .

Research has demonstrated that ATG14 depletion completely blocks autophagic fusion with lysosomes, underscoring its indispensable role in the complete autophagy process . From an evolutionary perspective, ATG14 is highly conserved, with orthologs identified across multiple species including mouse, rat, bovine, zebrafish, and chimpanzee, highlighting its fundamental importance in cellular homeostasis mechanisms .

What are the main applications for ATG14 antibodies in research?

ATG14 antibodies serve multiple research applications with varying optimization requirements:

Western Blot remains the most frequently utilized application, with over 150 citations in the literature describing its use for ATG14 detection . When designing experiments, researchers should consider that ATG14 antibody reactivity has been validated across human, mouse, and rat samples, making these antibodies versatile tools for comparative studies across model organisms .

How can researchers distinguish between the different isoforms of ATG14?

ATG14 exists in at least three different isoforms that researchers may need to differentiate:

Currently available antibodies typically detect all three isoforms of ATG14, but distinguishing between them requires careful experimental design . The canonical isoform has a predicted molecular weight of 55.3 kDa, though post-translational modifications often result in bands appearing at both 55 kDa and 65 kDa in Western blots . Researchers should be aware that the observed molecular weight may vary from the predicted weight due to post-translational modifications, cleavages, and relative charges .

For experiments requiring isoform-specific detection, consider these approaches:

• Use antibodies raised against isoform-specific regions (where epitopes differ between isoforms)

• Employ RT-PCR with isoform-specific primers as a complementary technique

• Perform 2D gel electrophoresis to separate isoforms based on both molecular weight and isoelectric point

• Consider using recombinant isoforms as positive controls to establish migration patterns

When publishing results involving ATG14, clearly specify which isoforms were detected and provide detailed methodological information to facilitate reproducibility.

What positive controls are recommended when validating ATG14 antibodies?

Proper controls are essential for validating ATG14 antibody specificity:

Based on validated research applications, the following positive controls are recommended for ATG14 antibody validation:

For experiments exploring autophagy activation, nutrient starvation (HBSS treatment for 2-4 hours) provides a physiological positive control that increases ATG14 activity . Conversely, negative controls should include ATG14 knockdown/knockout cells and isotype control antibodies to confirm specificity and rule out non-specific binding.

How can researchers investigate ATG14 phosphorylation and its impact on autophagy regulation?

ATG14 phosphorylation represents a critical regulatory mechanism in autophagy:

Research has demonstrated that ATG14 undergoes phosphorylation at Serine 29 during autophagy activation . This post-translational modification can be detected using phospho-specific antibodies, as evidenced in studies examining docosahexaenoic acid (DHA) effects on autophagy, where p-ATG14 (Ser29) levels were quantified alongside total ATG14 .

For comprehensive phosphorylation analysis, implement the following methodology:

• Use phospho-specific antibodies targeting known phosphorylation sites (e.g., Ser29)

• Employ phosphatase inhibitors in lysis buffers to preserve phosphorylation status

• Run parallel Western blots with phospho-specific and total ATG14 antibodies

• Calculate the ratio of phosphorylated to total ATG14 to quantify activation status

• Consider lambda phosphatase treatment as a negative control

Biological significance can be assessed by correlating ATG14 phosphorylation with downstream autophagy markers such as LC3-II/LC3-I ratio and p62/SQSTM1 degradation . When investigating kinase involvement, consider treatments with kinase inhibitors (e.g., ULK1 inhibitors) to determine pathway dependencies.

What are the methodological considerations for troubleshooting discrepancies in ATG14 molecular weight detection?

Researchers frequently encounter variability in ATG14 detection by Western blot:

While the calculated molecular weight of ATG14 is approximately 55 kDa, observed bands frequently appear at both 55 kDa and 65 kDa . This discrepancy requires careful interpretation and troubleshooting:

When encountering unexpected banding patterns, researchers should systematically address each potential variable and validate findings across multiple experimental conditions . Additionally, consider that different antibody clones may preferentially recognize specific conformations or post-translationally modified forms of ATG14, explaining variation between antibody products.

How can ATG14 antibodies be utilized to investigate the formation of PI3KC3-C1 complex?

The PI3KC3-C1 complex is crucial for autophagosome formation:

ATG14 directs the localization of the PI3-kinase complex PI3KC3-C1, which is essential for autophagosome biogenesis . Researchers can employ several approaches to study this complex:

• Co-immunoprecipitation (Co-IP): Use ATG14 antibodies to pull down the entire complex, followed by immunoblotting for other components (Beclin1, VPS34, VPS15)

  • Recommended antibody amount: 0.5-4.0 μg per 1.0-3.0 mg of protein lysate

  • Gentle lysis conditions preserve protein-protein interactions

• Proximity Ligation Assay (PLA): Visualize protein interactions in situ

  • Requires pairs of primary antibodies raised in different species

  • Provides spatial information about complex formation within cells

• Immunofluorescence co-localization: Track ATG14 localization relative to other complex components

  • Particularly useful for examining translocation to isolation membranes during autophagy induction

• Bimolecular Fluorescence Complementation (BiFC): For live-cell visualization of complex assembly

  • Requires genetic engineering but provides dynamic information

Under different autophagy conditions (starvation, rapamycin treatment, etc.), complex composition and localization can be monitored to understand regulatory mechanisms governing early autophagosome formation events.

What experimental design considerations are essential when studying ATG14 in neurodegenerative disease models?

Neurodegenerative diseases often involve autophagy dysfunction:

When investigating ATG14 in neurodegenerative conditions, researchers should implement tailored experimental designs:

• Model selection considerations:

  • Primary neurons vs. neuronal cell lines (different baseline autophagy)

  • Animal models with progressive neurodegeneration

  • Patient-derived iPSCs differentiated to relevant neural cell types

• Technical considerations for neural tissues:

  • Brain tissue requires optimized extraction methods to maintain protein integrity

  • Mouse and rat brain tissues have been validated as reliable sources for ATG14 detection

  • Immunohistochemistry protocols may require extended antigen retrieval

• Functional assessments:

  • Correlate ATG14 levels/activity with autophagic flux measurements

  • Assess ATG14 interaction with disease-specific proteins (e.g., tau, α-synuclein)

  • Monitor phosphorylated ATG14 (Ser29) levels as an indicator of autophagy activation

Recent research has demonstrated that therapies like docosahexaenoic acid (DHA) can increase basal autophagy levels, as evidenced by elevated phospho-ATG14 levels . When designing intervention studies, incorporate both total and phosphorylated ATG14 measurements alongside functional autophagy assays and disease-specific pathology markers.

How do different fixation methods affect ATG14 antibody performance in immunocytochemistry and immunohistochemistry?

Fixation significantly impacts ATG14 epitope accessibility and detection:

Different fixation methods can substantially affect ATG14 antibody binding in immunohistochemistry (IHC) and immunocytochemistry (ICC) applications:

For immunohistochemistry applications with formalin-fixed, paraffin-embedded (FFPE) tissues, antigen retrieval with TE buffer at pH 9.0 has been validated for optimal ATG14 detection, though citrate buffer at pH 6.0 can serve as an alternative . For immunofluorescence in human small intestine tissue, concentrations around 20 μg/mL have proven effective .

Researchers should perform side-by-side comparisons of different fixation protocols when optimizing for a new tissue type or cell line, as optimal conditions may vary depending on the specific antibody clone and target tissue.

How can ATG14 antibodies be employed in multiplexed immunofluorescence systems?

Multiplexed detection provides valuable insights into ATG14's relationships with other autophagy proteins:

When designing multiplexed immunofluorescence experiments for ATG14:

• Select primary antibodies raised in different host species to avoid cross-reactivity

• Consider using directly conjugated ATG14 antibodies when available

• For sequential staining protocols, ensure complete elution between rounds

• Include appropriate controls for spectral overlap and antibody cross-reactivity

• Use computational approaches for colocalization analysis (Pearson's coefficient, Mander's overlap)

This approach allows simultaneous visualization of ATG14 with other autophagy pathway components like Beclin1, LC3, and LAMP1, revealing spatial relationships during different stages of autophagy. When designing panels, consider ATG14's known subcellular localizations in the membrane, cytoplasmic vesicles, ER, and cytoplasm to select complementary markers for these compartments.

What approaches can be used to validate ATG14 antibody specificity for rigorous research applications?

Antibody validation is critical for reproducible research:

A comprehensive validation strategy for ATG14 antibodies should include:

For ATG14 antibodies specifically, the middle region (amino acids 270-320) has been validated as an effective immunogen region , and antibodies raised against this region have demonstrated specificity across multiple applications. When validating a new ATG14 antibody, researchers should at minimum perform Western blot on positive control tissues such as mouse brain tissue, A549 cells, or rat brain tissue, which have been consistently validated across different antibody products .

How can researchers quantitatively assess autophagy activation using ATG14 antibodies?

Quantitative assessment of autophagy via ATG14 requires multiparameter analysis:

To comprehensively evaluate autophagy activation using ATG14 antibodies:

• Western blot analysis:

  • Measure phospho-ATG14 (Ser29)/total ATG14 ratio

  • Normalize to appropriate loading controls

  • Compare with established autophagy markers (LC3-II/I ratio, p62 degradation)

• Flow cytometry:

  • Permeabilize cells and stain for phospho-ATG14

  • Allows single-cell analysis and population statistics

• Microscopy-based approaches:

  • Quantify ATG14 puncta formation (number, size, intensity)

  • Colocalization analysis with autophagosome markers

  • Live-cell imaging to track dynamics

• Functional correlation:

  • Correlate ATG14 measurements with autophagic flux assays

  • Use lysosomal inhibitors (Bafilomycin A1, Chloroquine) to assess completion of autophagy

Recent research examining DHA effects on autophagy demonstrated that comprehensive analysis should include measurements of multiple autophagy-related proteins, including ATG5, ATG12, ATG16L1, Beclin1, alongside both total ATG14 and p-ATG14 (Ser29) , providing a more complete picture of pathway activation.

How can ATG14 antibodies contribute to biomarker development in diseases associated with autophagy dysfunction?

ATG14 holds potential as a biomarker for autophagy-related conditions:

The dysregulation of autophagy has been linked to numerous diseases, including cancer, neurodegenerative disorders, and metabolic conditions . Developing ATG14-based biomarkers requires:

• Identification of disease-specific ATG14 alterations:

  • Expression level changes (up/down-regulation)

  • Post-translational modification patterns

  • Altered subcellular localization

  • Aberrant protein-protein interactions

• Establishing detection methods in clinical samples:

  • IHC protocols optimized for diagnostic pathology

  • Validated antibody panels for specific disease contexts

  • Standardized scoring systems for quantification

• Correlation with clinical outcomes:

  • Progression-free survival

  • Response to therapy

  • Disease recurrence

In liver cancer specifically, ATG14 detection by immunohistochemistry has been validated and could potentially serve as a prognostic or predictive biomarker . When developing such applications, researchers should employ antibodies with proven specificity and reproducibility across patient samples.

What methodological recommendations exist for studying ATG14 in patient-derived samples?

Patient-derived samples present unique challenges for ATG14 analysis:

When working with clinical specimens:

• Sample preservation considerations:

  • Flash freezing for protein analysis preserves post-translational modifications

  • Formalin fixation time affects epitope accessibility (standardize protocols)

  • Consider preparation of patient-derived cell lines for functional studies

• Protocol adaptations:

  • For FFPE tissues, extended antigen retrieval with TE buffer (pH 9.0) is recommended

  • Patient samples may require higher antibody concentrations than cell lines

  • Include tissue-matched controls whenever possible

• Interpretation challenges:

  • Account for patient heterogeneity and treatment history

  • Correlate with other autophagy markers for comprehensive analysis

  • Consider confounding factors (medications, comorbidities)

When examining ATG14 in human small intestine tissue by immunofluorescence, concentrations of approximately 20 μg/mL have been validated , but optimization may be required for different tissue types and preservation methods.

What are the current limitations and future directions in ATG14 antibody research?

Despite significant advances, several challenges and opportunities remain:

Current limitations in ATG14 antibody applications include the need for better isoform-specific detection, standardized protocols for quantitative assessment, and expanded validation across diverse tissue types. The development of antibodies that can distinguish between different phosphorylation states and conformational changes would significantly advance the field.

Future directions likely include:

• Development of more specific antibodies against post-translationally modified forms of ATG14

• Expansion of multiplexed detection systems for comprehensive autophagy pathway analysis

• Standardization of ATG14 measurement for potential clinical applications

• Integration with emerging technologies like spatial transcriptomics and proteomics

• Applications in therapeutic development targeting the autophagy pathway